Importantly, the landscape also yields clues towards potential drug targets (FLT3, NAALAD2, CX3CL1-CX3CR1, OPRM1, and HRH2) that can be further developed into TD treatments. Here, CX3CR1 is linked to thanatophoric dysplasia.